Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Amazon Great Indian Festival Celebration Sale - 2019
Google
Web www.equitybulls.com
Stock Report

| More

Zydus announces positive results from EVIDENCES IV Phase 2 clinical trial of Saroglitazar Magnesium in NAFLD and NASH

Posted On: 2019-10-03 09:30:26

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that Saroglitazar Magnesium has achieved the primary end-points in the EVIDENCES IV trial in patients with NAFLD and NASH.

The EVIDENCES IV NASH trial was a randomized, double-blind, placebo-controlled study that enrolled 106 patients with Non-Alcoholic Fatty Liver Disease (NAFLD), including Non-Alcoholic Steatohepatitis (NASH) across 20 clinical sites in the United States of America. Patients were randomly assigned in a ratio of 1:1:1:l to receive Saroglitazar Magnesium 1mg or 2 mg or 4 mg or matching placebo once daily in the morning before breakfast for 16 Weeks.

Prof. Naga P. Chalasani, MD, Associate Dean for Clinical Research and Director, Division of Gastroenterology & Hepatology, Indiana University School of Medicine, USA, an authority in the fields of NAFLD and drug induced liver injury (DILI), was the lead Principal Investigator of the EVIDENCES IV trial. Prof. Chalasani stated "Saroglitazar 4 mg significantly improved liver biochemistries, hepatic steatosis, dyslipidemia, and insulin resistance, with no weight gain or fluid retention. These results are quite encouraging as there is a significant unmet need for patients with NAFLD and NASH for a drug that improves not just the liver disease, but important comorbidities such as insulin resistance and dyslipidemia."

Speaking on the development, Mr. Pankaj R. Patel, Chairman, Zydus Group said, "We are happy with the positive results that Saroglitazar Magnesium has shown in the EVIDENCES IV trial. We look forward to presenting the detailed data in upcoming scientific conferences and publishing the study findings in peer-reviewed scientific journals."

The primary endpoint ofthe study was percentage change from baseline in serum ALT levels at Week 16 in the Saroglitazar Magnesium groups as compared to the placebo group. There was a statistically significant reduction in mean ALT from baseline to week 16 observed with all doses of Saroglitazar as compared to placebo.

A statistically significant reduction in hepatic fat content from baseline was observed in patients treated with Saroglitazar Magnesium as compared to placebo following 16 weeks of treatment as measured by MRI-PDFF. The secondary endpoints of the trial also included measurements of other Liver enzymes, Insulin resistance, Liver fibrosis, BMI, Waist circumference, MRI-derived measures oftotal liver fat index, Lipid and lipoprotein levels, and pharmacokinetic parameters.

This study is one of several EVIDENCES trials conducted to assess the effect of Saroglitazar Magnesium in various populations with NAFLD, including patients with NASH.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.233.05 as compared to the previous close of Rs. 233.45. The total number of shares traded during the day was 80419 in over 1313 trades.

The stock hit an intraday high of Rs. 237 and intraday low of 228. The net turnover during the day was Rs. 18734405.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

MCX Q2 FY2019-20 consolidated PAT surges to Rs. 71.75 crore

ACC Ltd Q3 consolidated PAT at Rs. 302.53 crore

Uttam Galva Steels Ltd posts loss of Rs. 335.45 crores in Q2

SBI Life Insurance Company Ltd announces performance for half year ended Sep 30, 2019

CRISIL reaffirms ratings of Raymond's bank loan facilities

Hindustan Zinc Ltd Board to consider Q2 results & First Interim Dividend on Oct 21, 2019

ARSS Infrastructure Projects Ltd's JV receives work order of Rs. 60.57 crore

ACC Ltd announces Q3 CY2019 results

Robust Volumes on MCX Drive Strong Performance in Q2 FY 2020

ONGC Videsh makes two new discoveries in Colombia and Brazil

Suditi Industries Ltd updates on ratings by CARE

Thangamayil Jewellery Ltd to open two new branches on Oct 16, 2019

Gujarat Hotels Ltd Q2 net profit rises to Rs. 1.07 crore

Wipro Limited Q2 Net Income at Rs. 25.5 billion

Karnataka Bank records first half net profit of Rs. 281.33 crore

Scanpoint Geomatics bags contract for Rs. 3.99 crore

ARSS Infrastructure Projects Ltd's JV bags order of Rs. 50.46 crore

Karnataka Bank reports net profit of Rs. 105.91 crore

Alicon Castalloy Ltd reports consolidated Q2 PAT of Rs. 9.35 crore

WIPRO Ltd Q2 consolidated PAT climbs to Rs. 2552.7 crore

Dhanvarsha Finvest Ltd assigned credit rating for proposed long term facility

ICRA Credit Rating for Rs 500 Crore bank facilities of Ramco Industries Limited

Dhanvarsha Finvest Ltd posts net profit of Rs. 1.03 crore in Q2

International Travel House Ltd Q2 loss at Rs. (2.12) crore

Paisalo Digital Ltd posts consolidated Q2 PAT of Rs. 20.04 crores

Apollo Tricoat Tubes Ltd Q2 net profit jumps to Rs. 9.42 crores

Equinor extends IT Operations and Transformation Agreement with HCL

Network18 Media & Investments Ltd announces Q2 FY2019-20 results

TV18 Broadcast Limited announces Q2 FY20 results

G G Engineering Ltd acquires additional stake in Shashi Beriwal and Company Pvt Ltd

Z F Steering Gear India Ltd posts loss of Rs. 0.80 crore in Q2

Berger Paints India Ltd to acquire STP Limited for Rs. 167.5 crore

Kaveri Seeds sets up its biggest, technologically advanced Biotechnology lab in Telangana, strengthens its focus on R & D

Maruti Suzuki invests Rs. 154 crore towards CSR initiatives in FY 2018-19

IOL Chemicals & Pharmaceuticals Ltd prepays Rs. 22.11 crore to bank

Jindal Drilling and Industries Limited awarded contract for Offshore Drilling Rig

CARE reaffirms ratings of Havells India Ltd

Indiabulls Housing Finance Limited repays Rs. 1330 crores raised through masala bonds

YES BANK recovers INR 645 crore

Vikas WSP Ltd receives LoC for $30 mn

CRISIL upgrades ratings of Varun Beverages Ltd

HUL Announces Key Appointments to Management Committee

GTPL Hathway appoints Mr. Anil Bothra as its Chief Financial Officer

Brickwork reaffirms ratings of Transcorp International Ltd

TCS Named India's Overall Most Outstanding Company in Asiamoney's 2019 Poll

Tejas Networks launches World's Largest Disaggregated Packet-Optical Switch at India Mobile Congress 2019

Cummins India powering a cleaner and more prosperous India with their BS-VI Certified engines

Early Diwali for investors: IRCTC stock doubles on listing day

Hindustan Unilever Ltd board declares interim dividend of Rs. 11 for 2019-20

Thomas Cook India introduces a unique 'Double Protection Program' comprising Trip Protection + Guaranteed Departures aimed at protecting traveller interests







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019